DelveInsight’s, “Tendinopathy Pipeline Insight, 2022,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in the Tendinopathy pipeline landscape.

 

Tendinopathy Pipeline Insight, 2022″ report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Tendinopathy pipeline landscape is provided which includes the disease overview and Tendinopathy treatment guidelines. The assessment part of the report embraces, in depth Tendinopathy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Tendinopathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Key takeaways from the Tendinopathy Pipeline Report

• DelveInsight’s Tendinopathy pipeline report depicts a robust space with 05+ active players working to develop 05+ pipeline therapies for Tendinopathy treatment.
• Leading Tendinopathy Companies such as MiMedx Group, R3 Stem Cell, Novartis Pharmaceuticals, University of Wisconsin-Madison, General Electric, Ipsen, Orthocell Limited, and others are developing novel products to improve the Tendinopathy treatment pipeline outlook.
• The promising Tendinopathy therapies in the pipeline includes Secukinumab, ESWT, Etoricoxib, Diclofenac, SM04755, and others
• The Tendinopathy Pipeline Report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Tendinopathy therapeutic drugs key players involved in developing key drugs.
• The Tendinopathy Pipeline Report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Tendinopathy drugs.
• The Tendinopathy pipeline possesses potential drugs as monotherapies as well as combination therapies.

 

Latest Breakthroughs & Developments in the Tendinopathy Treatment Landscape

• dHACM is a micronized dehydrated Human Amnion Chorion Membrane developed by MiMedx for Tendinitis and is currently in the phase III stage of development. AmnioFix is processed using Purion, a unique patented method for placental-based allografts according to the American Association of Tissue Banks (AATB) standards.
• The product is derived from donated C-sections of live births in the US. The product faces active preservation of the extracellular matrix (ECM), regulatory proteins, and elimination of blood contaminants through a proprietary cleansing process. For an additional level of safety, the product is terminally sterilized.

 

Request a Sample Copy and discover the recent advances in the Tendinopathy pipeline report @ Tendinopathy Emerging Therapies

 

Tendinopathy Overview

Tendinopathies are very common in general population and a huge number of tendon-related procedures take place annually worldwide, with significant socio-economic repercussions. Numerous treatment options are commonly used for tendon disorders. Tendon disorders are a class of pathology that includes traumatic injuries as well as chronic diseases, such as tendinopathy. They represent some of the most frequent orthopedic diagnosis, accounting for over 30% of all musculoskeletal consultations. Over 30 million human tendon-related procedures take place annually worldwide with significant socio-economic repercussions in terms of lost working hours and economic expenditure. Numerous treatment options are proposed in the treatment of patients affected by tendinopathies. Usually, they can be grouped in pharmacological therapies, physical therapies, and therapeutic exercise.

 

Tendinopathy Pipeline Insight Report

“Tendinopathy – Pipeline Insight, 2022” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Tendinopathy pipeline landscape is provided which includes the disease overview and Tendinopathy treatment guidelines. The assessment part of the report embraces, in depth Tendinopathy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Tendinopathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Tendinopathy Emerging Drugs 

• dHACM: MiMedx

 

Find out more about the disease and recent developments @ Tendinopathy Pipeline Assessment

 

 

DelveInsight’s report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Tendinopathy Route of Administration

• Oral
• Intravenous
• Subcutaneous

 

 Tendinopathy Molecule Type

• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy

 

Scope of the Tendinopathy Pipeline Report

• Coverage- Global
• Tendinopathy Companies- MiMedx Group, R3 Stem Cell, Novartis Pharmaceuticals, University of Wisconsin-Madison, General Electric, Ipsen, Orthocell Limited, and others
• Tendinopathy Therapies- Secukinumab, ESWT, Etoricoxib, Diclofenac, SM04755, and others
• Tendinopathy Therapeutic Assessment by Product Type
• Tendinopathy Therapeutic Assessment by Stage and Product Type
• Tendinopathy Therapeutic Assessment by Route of Administration
• Tendinopathy Therapeutic Assessment by Stage and Route of Administration
• Tendinopathy Therapeutic Assessment by Molecule Type
• Tendinopathy Therapeutic Assessment by Stage and Molecule Type
• Tendinopathy companies’ collaborations, Licensing, Acquisition -Deal Value Trends
• Tendinopathy – Market Drivers and Barriers
• Tendinopathy – Future Perspectives and Conclusion

 

Table of Content

1. Introduction
2. Executive Summary
3. Tendinopathy: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Tendinopathy– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. dHACM: MiMedx
9. Mid Stage Products (Phase II)
10. SI-613: Seikagaku Corporation
11. Early Stage Products (Phase I/II)
12. Drug name: Company name
13. Preclinical Stage Products
14. Drug name: Company name
15. Inactive Products
16. Tendinopathy Key Companies
17. Tendinopathy Key Products
18. Tendinopathy- Unmet Needs
19. Tendinopathy- Market Drivers and Barriers
20. Tendinopathy- Future Perspectives and Conclusion
21. Tendinopathy Analyst Views
22. Tendinopathy Key Companies
23. Appendix

 

For further information on the Tendinopathy Pipeline therapeutics, reach out to Tendinopathy Drugs

 

About Us 

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/